Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation

Aim. Evaluation of the efficacy and safety of the modified refralon administration protocol for the relief of paroxysmal atrial fibrillation (AF). Materials and methods. The study included 39 patients (19 men, mean age 6312.8 years). All patients, after excluding contraindications in the intensiv...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Khava M. Dzaurova, Nikolay Yu. Mironov, Yuliia A. Yuricheva, Vladislav V. Vlodzyanovsky, Nataliia A. Mironova, Lada Yu. Laiovich, Tatiana A. Malkina, Liudmila V. Zinchenko, Sergei F. Sokolov, Sergey P. Golitsyn
Formato: article
Lenguaje:RU
Publicado: "Consilium Medicum" Publishing house 2021
Materias:
R
Acceso en línea:https://doaj.org/article/6b4b489736104a66bec087582d7c3b89
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6b4b489736104a66bec087582d7c3b89
record_format dspace
spelling oai:doaj.org-article:6b4b489736104a66bec087582d7c3b892021-12-01T12:22:36ZEfficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation0040-36602309-534210.26442/00403660.2021.09.201008https://doaj.org/article/6b4b489736104a66bec087582d7c3b892021-09-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/82970/63449https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342Aim. Evaluation of the efficacy and safety of the modified refralon administration protocol for the relief of paroxysmal atrial fibrillation (AF). Materials and methods. The study included 39 patients (19 men, mean age 6312.8 years). All patients, after excluding contraindications in the intensive care unit, were injected intravenously with refralon at an initial dose of 5 mg/kg. If AF was preserved and there were no contraindications, after 15 min, repeated administration was performed at a dose of 5 mg/kg (total dose of 10 mg/kg). After another 15 min, while maintaining AF and the absence of contraindications, the third injection of the drug was performed at a dose of 10 mg/kg (total dose of 20 mg/kg). In the absence of relief and the absence of contraindications, another injection of refralon at a dose of 10 mg/kg was performed after another 15 min (in this case, the maximum total dose of 30 mg/kg was reached). After each injected bolus and before the introduction of the next one, the ECG parameters and the general condition of the patient were assessed. The patient was monitored for 24 hours to exclude the arrhythmogenic effect and other possible adverse events. Results. Restoration of sinus rhythm (SR) was noted in 37 patients out of 39 (95%). Of these, 19 people (48.7%) had SR recovery after the administration of a minimum dose of refralone of 5 mg/kg. The effectiveness of the total dose of 10 mg/kg was 76.9%, the dose of 20 mg/kg was 89.7%, and the dose of 30 mg/kg was 95%. Only two patients did not recover HR after administration of the maximum dose of refralon 30 mg/kg. Pathological prolongation of the QTc interval (500 ms) was recorded in 5% of patients. Not a single case of ventricular arrhythmogenic action (induction of Torsade de pointes) has been reported. Bradyarrhythmias (pauses, bradycardia) were registered in 13% of cases, were of a transient nature. Conclusion. Refralon has a high efficiency of relief (95%) of paroxysmal AF, while in almost half of cases (48.7%), SR recovery is achieved using the minimum dose of refralon 5 mg/kg. Despite the prolongation of the QTc500 ms recorded in 5% of cases, none of the patients developed Torsade de pointes after administration of the drug.Khava M. DzaurovaNikolay Yu. MironovYuliia A. YurichevaVladislav V. VlodzyanovskyNataliia A. MironovaLada Yu. LaiovichTatiana A. MalkinaLiudmila V. ZinchenkoSergei F. SokolovSergey P. Golitsyn"Consilium Medicum" Publishing housearticleatrial fibrillationparoxysmal formrelief of paroxysmal formantiarrhythmic drugrefralonMedicineRRUТерапевтический архив, Vol 93, Iss 9, Pp 1052-1057 (2021)
institution DOAJ
collection DOAJ
language RU
topic atrial fibrillation
paroxysmal form
relief of paroxysmal form
antiarrhythmic drug
refralon
Medicine
R
spellingShingle atrial fibrillation
paroxysmal form
relief of paroxysmal form
antiarrhythmic drug
refralon
Medicine
R
Khava M. Dzaurova
Nikolay Yu. Mironov
Yuliia A. Yuricheva
Vladislav V. Vlodzyanovsky
Nataliia A. Mironova
Lada Yu. Laiovich
Tatiana A. Malkina
Liudmila V. Zinchenko
Sergei F. Sokolov
Sergey P. Golitsyn
Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation
description Aim. Evaluation of the efficacy and safety of the modified refralon administration protocol for the relief of paroxysmal atrial fibrillation (AF). Materials and methods. The study included 39 patients (19 men, mean age 6312.8 years). All patients, after excluding contraindications in the intensive care unit, were injected intravenously with refralon at an initial dose of 5 mg/kg. If AF was preserved and there were no contraindications, after 15 min, repeated administration was performed at a dose of 5 mg/kg (total dose of 10 mg/kg). After another 15 min, while maintaining AF and the absence of contraindications, the third injection of the drug was performed at a dose of 10 mg/kg (total dose of 20 mg/kg). In the absence of relief and the absence of contraindications, another injection of refralon at a dose of 10 mg/kg was performed after another 15 min (in this case, the maximum total dose of 30 mg/kg was reached). After each injected bolus and before the introduction of the next one, the ECG parameters and the general condition of the patient were assessed. The patient was monitored for 24 hours to exclude the arrhythmogenic effect and other possible adverse events. Results. Restoration of sinus rhythm (SR) was noted in 37 patients out of 39 (95%). Of these, 19 people (48.7%) had SR recovery after the administration of a minimum dose of refralone of 5 mg/kg. The effectiveness of the total dose of 10 mg/kg was 76.9%, the dose of 20 mg/kg was 89.7%, and the dose of 30 mg/kg was 95%. Only two patients did not recover HR after administration of the maximum dose of refralon 30 mg/kg. Pathological prolongation of the QTc interval (500 ms) was recorded in 5% of patients. Not a single case of ventricular arrhythmogenic action (induction of Torsade de pointes) has been reported. Bradyarrhythmias (pauses, bradycardia) were registered in 13% of cases, were of a transient nature. Conclusion. Refralon has a high efficiency of relief (95%) of paroxysmal AF, while in almost half of cases (48.7%), SR recovery is achieved using the minimum dose of refralon 5 mg/kg. Despite the prolongation of the QTc500 ms recorded in 5% of cases, none of the patients developed Torsade de pointes after administration of the drug.
format article
author Khava M. Dzaurova
Nikolay Yu. Mironov
Yuliia A. Yuricheva
Vladislav V. Vlodzyanovsky
Nataliia A. Mironova
Lada Yu. Laiovich
Tatiana A. Malkina
Liudmila V. Zinchenko
Sergei F. Sokolov
Sergey P. Golitsyn
author_facet Khava M. Dzaurova
Nikolay Yu. Mironov
Yuliia A. Yuricheva
Vladislav V. Vlodzyanovsky
Nataliia A. Mironova
Lada Yu. Laiovich
Tatiana A. Malkina
Liudmila V. Zinchenko
Sergei F. Sokolov
Sergey P. Golitsyn
author_sort Khava M. Dzaurova
title Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation
title_short Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation
title_full Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation
title_fullStr Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation
title_full_unstemmed Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation
title_sort efficiency and safety of using the modified protocol for the administration of the domestic class iii antiarrhythmic drug for the relief of paroxysmal atrial fibrillation
publisher "Consilium Medicum" Publishing house
publishDate 2021
url https://doaj.org/article/6b4b489736104a66bec087582d7c3b89
work_keys_str_mv AT khavamdzaurova efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT nikolayyumironov efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT yuliiaayuricheva efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT vladislavvvlodzyanovsky efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT nataliiaamironova efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT ladayulaiovich efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT tatianaamalkina efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT liudmilavzinchenko efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT sergeifsokolov efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
AT sergeypgolitsyn efficiencyandsafetyofusingthemodifiedprotocolfortheadministrationofthedomesticclassiiiantiarrhythmicdrugforthereliefofparoxysmalatrialfibrillation
_version_ 1718405178038681600